Keenova Therapeutics Plc Revenue Growth Rates (MNK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Keenova Therapeutics Plc  (MNK)
 

MNK's Revenue Growth by Quarter and Year

Keenova Therapeutics Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNK Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 467.60
FY 467.60





MNK Revenue first quarter 2026 Y/Y Growth Comment
Keenova Therapeutics Plc reported decrease in Revenue in the first quarter 2026 by -7.42% to $ 467.60 millions, from the same quarter in 2025.
The decrease in the first quarter 2026 Keenova Therapeutics Plc's Revenue compares unfavorably to the Company's average Revenue decrease of -5.89%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 110 other companies have achieved higher Revenue growth. While Keenova Therapeutics Plc' s Revenue decline of -7.42% ranks overall at the positon no. 2094 in the first quarter 2026.


MNK Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - 8.23 % 24.03 %
3rd Quarter September - 61.24 % 10.19 % -13.63 %
2nd Quarter June - -48.36 % -6.59 % -
1st Quarter March -7.42 % 1.67 % 6.95 % -
FY   - -36.69 % 2.56 % -

Financial Statements
Keenova Therapeutics Plc's first quarter 2026 Revenue $ 467.60 millions MNK's Income Statement
Keenova Therapeutics Plc's first quarter 2025 Revenue $ 505.10 millions Quarterly MNK's Income Statement


MNK Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - - 10.06 % 12.06 %
3rd Quarter September - 79.33 % -42.57 % -51.32 %
2nd Quarter June - -16.87 % 63.69 % 87.43 %
1st Quarter March - -1.73 % 4.61 % 21.31 %
FY (Year on Year)   - -36.69 % 2.56 % -


Back to MNK Growth rate Comparisons >> Back to MNK Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #111
Healthcare Sector #321
Overall #2094

Revenue Y/Y Growth Statistics
High Average Low
5.14 % -5.89 % -20.93 %
(Mar 29 2024)   (Mar 31 2026)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #111
Healthcare Sector #321
Overall #2094
Revenue Y/Y Growth Statistics
High Average Low
5.14 % -5.89 % -20.93 %
(Mar 29 2024)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Keenova Therapeutics Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
163.44 % 14.05 % -76.43 %
(Mar 31 2026)  


MNK's I. Quarter Q/Q Revenue Comment
Improvement I. Quarter 2026where Keenova Therapeutics Plc published Revenue of $ 467.60 millions should is starting point of positive performance.Keenova Therapeutics Plc announced in the I. Quarter 2026 Revenue of $ 467.60 millions compare to recorded in previos quarter.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Keenova Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 66.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #27
Overall #66
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #27
Overall #66
Revenue Q/Q Growth Statistics
High Average Low
163.44 % 14.05 % -76.43 %
(Mar 31 2026)  


MNK's I. Quarter Q/Q Revenue Comment
Improvement I. Quarter 2026where Keenova Therapeutics Plc published Revenue of $ 467.60 millions should is starting point of positive performance.Keenova Therapeutics Plc announced in the I. Quarter 2026 Revenue of $ 467.60 millions compare to recorded in previos quarter.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Keenova Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 66.


Keenova Therapeutics Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 26 2025)		 12 Months Ending
(Mar 28 2025)		 12 Months Ending
(Sep 27 2024)
Cumulative Revenue 12 Months Ending $ 1,413.00 $ 1,450.50 $ 2,192.00 $ 1,906.00 $ 2,299.30
Y / Y Revenue Growth (TTM) -38.55 % -36.69 % -2.66 % -13.7 % 1.47 %
Year on Year Revenue Growth Overall Ranking # 2485 # 1973 # 1216 # 2497 # 1579
Seqeuential Revenue Change (TTM) -2.59 % -33.83 % 15.01 % -17.11 % 0.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 2605 # 2050 # 1474 # 2023 # 1580


Cumulative Revenue growth Comment
Keenova Therapeutics Plc's cumulative 12 months Revenue continue to drop, but on the faster rate at -38.55% year on year, at Mar 31 2026 compare to the -36.69% decrease at Dec 31 2025. If the Keenova Therapeutics Plc's fiscal year would end at Mar 31 2026, annual Revenue would be $1,413 millions.

In the Healthcare sector 357 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1973 to 2485.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 358
Overall # 2485

Revenue TTM Y/Y Growth Statistics
High Average Low
5.14 %
 -10.3 %
-38.55 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2605
Cumulative Revenue growth Comment
Keenova Therapeutics Plc's cumulative 12 months Revenue continue to drop, but on the faster rate at -38.55% year on year, at Mar 31 2026 compare to the -36.69% decrease at Dec 31 2025. If the Keenova Therapeutics Plc's fiscal year would end at Mar 31 2026, annual Revenue would be $1,413 millions.

In the Healthcare sector 357 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1973 to 2485.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 358
Overall # 2485

Revenue TTM Y/Y Growth Statistics
High Average Low
5.14 %
-10.3 %
-38.55 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2605




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MNK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Keenova Therapeutics Plc Revenue Growth Rates (MNK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Keenova Therapeutics Plc (CIK 1567892).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-055614
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Keenova Therapeutics Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.